Page last updated: 2024-10-25
dapsone and Tuberculosis, Drug-Resistant
dapsone has been researched along with Tuberculosis, Drug-Resistant in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Diacon, AH | 1 |
| Donald, PR | 1 |
| Pym, A | 1 |
| Grobusch, M | 1 |
| Patientia, RF | 1 |
| Mahanyele, R | 1 |
| Bantubani, N | 1 |
| Narasimooloo, R | 1 |
| De Marez, T | 1 |
| van Heeswijk, R | 1 |
| Lounis, N | 1 |
| Meyvisch, P | 1 |
| Andries, K | 1 |
| McNeeley, DF | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Failure or Recurrence (FoR)
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
Failure or Recurrence (FoR)
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
Favourable Outcome After Long-term Follow-up (132 Weeks)
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
Proportion of Patients With Acquired Drug Resistance
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
Trials
1 trial available for dapsone and Tuberculosis, Drug-Resistant